TH-1

Thorium-227, the basis of our second alpha-pharmaceutical platform, is a radionuclide that emits high-energy alpha particles. By linking thorium-227 to tumor-targeting molecules such as monoclonal antibodies, Algeta has the potential to create a pipeline of new generation alpha-pharmaceuticals with the potential to specifically seek and destroy cancers while minimizing damage to surrounding healthy tissues.

Conjugation of thorium-227 to targeting molecules has the potential to enhance the effectiveness of treatment for a wide and broad variety of cancer types. Therefore, the technology has the potential to generate variety of proprietary drug candidates for development by Algeta.

At the Society for Nuclear Medicine meeting in Toronto in June 2009, the targeted cancer cell-killing effect of thorium-227 conjugated to trastuzumab was presented for the first time and suggested that further studies be conducted with an alpha-pharmaceutical as a novel treatment for breast cancer.

Algeta is currently finalizing its strategy for the development of a future pipeline of alpha-pharmaceutical candidates based on thorium-227 through the selective in-licensing and/or acquiring of innovative technologies and tumor-targeting molecules.